Anti-Müllerian hormone (AMH): biomarker of true ovarian reserve.

5 Nov, 2018


no comments

Coming soon: Anti-Müllerian Hormone MAbs and Recombinant Protein.

Anti-Müllerian hormone (AMH) is increasingly utilized as a biomarker of women’s reproductive health. AMH levels correlate to the size of the follicle pool. In addition, it can be used to assess the response of in vitro fertility treatment.

Anti-Mullerian Hormone (AMH) is expressed by granulosa cells. Production declines when follicles are selected for dominance and when estrogen production starts to escalate. A contribution to this switch may be one of the functions of AMH. Large follicles produce little AMH, persisting only in the cumulus cells surrounding the oocyte. Thus, AMH does not show clinically relevant changes across the menstrual cycle. This greatly adds to its clinical utility, particularly compared to FSH, the historically established maker of ovarian reserve.

Advanced ImmunoChemical will soon launch reagents that allow the development of sensitive AMH immunoassays: monoclonal antibodies specific to AMH and a recombinant AMH protein. Please visit our website at

Best regards,

Anne Tolles, M.Sc./President

Skip to toolbar